Credits: canva
High-intensity drinking is worse than binge drinking. But what exactly does it mean? High intensity is defined as consuming an excessive number of drinks in one session: eight or more for women and ten or more for men.
While binge drinking is characterized by having four or five drinks within two hours.
This distinction emerged as researchers noticed that many of the severe consequences associated with binge drinking—like blackouts and alcohol poisoning—were linked to much higher levels of alcohol intake.
Heavy drinking habits, formerly associated with youth, are changing. Recent studies show that, while high-intensity drinking has decreased among young adults, it is still common among those in their late twenties. Almost one out of every eight people aged 27 to 28 consume 10 or more drinks every session.
Middle-aged individuals are drinking more heavily. It is more prominent in males over 30 and women aged 18 to 64.
The trend can be seen where the middle-aged uses alcohol as a tool to cope with the day-to-day life, whereas for youth, it is to have fun and to explore the adult life.
High-intensity drinking carries a greater risk than regular binge drinking. It is because when you consume such large volumes of alcohol in such a short period of time, it can boost blood alcohol concentration (BAC) to dangerous levels, usually exceeding 0.2%, as opposed to 0.08% for ordinary binge drinking.
This high BAC level increases the risk of disastrous effects, including:
Moreover, repeated high-intensity drinking significantly raises the risk of developing alcohol use disorder and contributes to broader societal harms such as relationship issues, property damage, and physical assaults.
The reason why one opts for high-intensity drinking patterns varies by age. For youth, it is mostly peer pressure and seeking fun. However it does have its own downsides.
For middle-aged and older adults, stress, life pressures, and emotional coping mechanisms are more common drivers. However, studies have shown that alcohol does not help you cope with stress. These motivations highlight the evolving role of alcohol as a tool for both celebration and self-medication, depending on the stage of life.
The rise of high-intensity drinking underscores the importance of addressing its unique dangers. While binge drinking is risky, consuming eight or more drinks exponentially increases the likelihood of harm. Experts emphasize that the “dose makes the poison,” and this extreme form of alcohol use deserves heightened attention.
By understanding the motivations and risks associated with high-intensity drinking, individuals can make informed decisions and seek support if needed, particularly during festive seasons that often encourage overindulgence.
Credit: iStock
If you think that injections of botulinum toxin -- commonly known as Botox -- are only used to make skin wrinkle-free, you may be mistaken.
A new study led by US researchers has shown that Botox injections can act as a “rescue therapy” to treat conditions such as finger ulcers, digital ischemia, and gangrene that are difficult to manage with standard therapies.
Finger ulcers (or digital ulcers) are painful open sores, while acute digital ischemia causes the fingers to become extremely painful, cold, and sometimes pale or bluish in color. Gangrene is the dangerous death of body tissue (necrosis), often turning skin black, green, or purple.
These debilitating complications, often associated with conditions like lupus, rheumatoid arthritis, systemic sclerosis, or bacterial infections, are caused by reduced blood flow to the fingers and heal poorly.
Botox injections, which work by reducing blood vessel constriction and improving circulation, may help achieve complete healing of lesions in more than 85 percent of such patients, according to a study recently published in JAMA Dermatology.
“These new findings are particularly important because therapeutic options remain limited for the cutaneous and vascular manifestations of systemic sclerosis and other autoimmune diseases,” said Dr. Netchiporouk, a scientist in the Infectious Diseases and Immunity in Global Health Program at the Research Institute of the McGill University Health Center.
Netchiporouk noted that the available vasodilator and immunosuppressive treatments are generally administered intravenously.
In contrast to Botox injections, these are also costly, minimally effective, and associated with significant adverse effects.
Also read: Botox Helped Her Burp: How Injectables Changed A 25-Year-Old's Life
The study also described the case of a 50-year-old man with a rare autoimmune disease that caused joint pain and digital necrosis (gangrene).
While traditional medications helped reduce his pain, he was forced to stop working, and the condition severely impacted his quality of life.
However, after receiving botulinum toxin injections, his pain was relieved, and sensation improved within 24 hours, and the necrosis began to improve within two weeks.
“This treatment has become an important tool, especially for patients with autoimmune vascular diseases that result in serious health consequences and for which there are few therapeutic options,” Netchiporouk said.
Also read: Why Regulatory Clarity Is Important for Safe Aesthetic Procedures in India
The study, based on a systematic review and individual patient data meta-analysis of 30 published studies and one unpublished case involving 119 patients, found that only a few patients experienced adverse effects.
These were generally mild and short-lived, most commonly temporary muscle weakness or pain at the injection site.
“Our results show that botulinum toxin can improve blood circulation in the fingers and treat serious complications such as ulcers or gangrene, offering a safe and easy-to-administer alternative,” said Dr. Catherine Zhu, a dermatology resident at the McGill University Health Center.
Zhu added that the injections can be easily administered by rheumatologists and dermatologists in outpatient settings, reducing reliance on intravenous therapies that require hospitalization and increasing overall healthcare costs.
Importantly, in most cases, a single injection session was sufficient to achieve the desired response.
“Botulinum toxin can offer significant benefits with a favorable safety profile. It deserves further study to develop standardized protocols and optimize outcomes,” said Dr. Netchiporouk.
Credit: iStock
Even after being preventable and curable, tuberculosis (TB) retains its status as one of the deadliest infectious diseases more than 140 years after Robert Koch announced the discovery of Mycobacterium tuberculosis (Mtb) on March 24, 1882.
A major challenge is that millions of people carry it without knowing, and current tests often miss it. This is known as latent TB infection, where bacteria exist in an inactive state in the body.
While you do not feel sick, the infection can progress to active, contagious TB disease.
Ahead of World Tuberculosis Day, on March 24, scientists at the Indian Council of Medical Research-National Institute for Research in Tuberculosis (NIRT) in Chennai, reported developing an advanced blood test that can find TB even when it's hiding, and before it gets serious.
In the study, published in the Lancet journal eBioMedicine, the researchers explained about detecting circulating cell-free Mtb DNA in the plasma of individuals at high risk of developing TB disease via a dual target-based digital droplet PCR (ddPCR) assay.
The test was targeted at adults without a clear diagnosis of TB (asymptomatic or clinically diagnosed TB).
Using the test, the team led by Luke Elizabeth Hanna from NIRT's Department of Virology and Biotechnology, found TB in the blood up to 18 months before a person was diagnosed.
They identified eight out of 10 people at risk - all before they fell sick with the infectious disease.
“The new test performed better than all existing standard TB tests combined. This test could change how we fight TB - by finding it early, treating it faster, and stopping it from spreading,” said the team in the paper.
Detection of pathogen-derived cell-free DNA (cfDNA) has been gaining much attention in recent years for the diagnosis of several clinical conditions.
cfDNA is a liquid biopsy blood test that analyzes small, non-cellular DNA fragments circulating in the bloodstream.
The team found that the advanced blood test could find tiny traces of TB in the blood - even when a person feels completely healthy.
The test works by breaking a small blood sample into thousands of tiny droplets and searching each one for TB.
The study included 46 healthy household contacts of patients with pulmonary TB who developed TB within two years of follow-up, and 92 HHCs who did not progress to TB.
Plasma was obtained and subjected to testing using a ddPCR assay targeting two Mtb-specific insertion sequences, IS6110 and IS1081.
"Our findings support the diagnostic utility of ddPCR-based detection of circulating Mtb-derived cell-free DNA in plasma of individuals at high risk for progressing to active TB several months prior to clinical diagnosis," the ICMR-NIRT researchers said.
"These findings address important unmet diagnostic needs and indicate the potential of plasma-based Mtb ccfDNA detection to contribute to improved TB case detection and progress towards the WHO End TB goals," they added.
In 2024, an estimated 10.7 million people fell ill with TB worldwide, including 5.8 million men, 3.7 million women and 1.2 million children. TB is present in all countries and age groups, according to the World Health Organization (WHO).
The WHO aims to End TB by 2035, with a 95 percent reduction in deaths and a 90 percent reduction in incidence compared to 2015.
Credit: iStock
Down Syndrome is a common genetic disorder in which an extra copy of chromosome 21 (Trisomy 21) causes mild-to-moderate intellectual disabilities, developmental delays, and characteristic physical traits.
Every year, World Down Syndrome Day is observed on March 21 every year to raise public awareness about the condition, which deserves more than medical care.
The theme for World Down Syndrome Day 2026 is 'Together Against Loneliness,’ and it focuses on raising awareness of how loneliness disproportionately affects people with Down syndrome and other intellectual disabilities, as well as their families.
According to the UN data, the estimated incidence of Down syndrome is between 1 in 1,000 -- 1 in 1,100 live births worldwide. Each year, approximately 3,000 to 5,000 children are born with this chromosome disorder.
In India, about 30,000 babies are born with Down syndrome every year.
While Down Syndrome is not preventable, in a video post on the social media platform X, Dr. Neerja Gupta from AIIMS Delhi highlighted the importance of early detection, screening, and long-term support for better outcomes.
Dr. Gupta, Professor, Division of Genetics at AIIMS's Department of Pediatrics, also explained the causes of the condition and shared tests that can help eliminate the risks in future babies.
“Down syndrome is a common chromosomal disorder in which chromosome 21 is present in three copies instead of two. Normally, every human cell has 46 chromosomes. However, in Down syndrome, there are 47 chromosomes because the 21st chromosome is present in three copies instead of two,” she said.
Due to the increase in the number of chromosomes, the child may:
"The sooner we can catch them, the earlier we can begin the intervention, resulting in better health outcomes," Dr Gupta said.
Down syndrome can occur in three types, depending on how the extra copy of chromosome 21 is present. In all cases, chromosome 21 appears in three copies, but this can happen in different ways.
"As the mother’s age increases, the risk of Down syndrome also increases. Today, there are several prenatal tests available to detect this condition during pregnancy," the expert said.
"In this, the DNA is seen in the fetal baby's stomach through the mother's blood, to check whether the chromosomal copies are in the right number or not," she said.
The expert noted that this screening test is highly accurate, but if the results indicate a high risk, diagnostic testing of the fetus is recommended.
© 2024 Bennett, Coleman & Company Limited